References of "Beguin, Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailNon-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial.
Willems, Evelyne ULg; Baron, Frédéric ULg; Baudoux, Etienne ULg et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2009), 23(3), 608-10

Detailed reference viewed: 76 (38 ULg)
Full Text
Peer Reviewed
See detailMatched unrelated donor stem cell transplant in 131 patients with follicular lymphoma : an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Avivi, Irit; Montoto, Silvia; Canals, Carme et al

in British Journal of Haematology (2009), 147

Matched unrelated donor stem cell transplantation (MUD-SCT) provides the only curative option for patients with follicular lymphoma (FL) who fail conventional therapies and do not have a siblong donor ... [more ▼]

Matched unrelated donor stem cell transplantation (MUD-SCT) provides the only curative option for patients with follicular lymphoma (FL) who fail conventional therapies and do not have a siblong donor. The purpose of this study was to analyse the outcome of patients with FL treated with MUD-SCT included in the European Group for Blood and Marrow Transplantation registry. 131 patients treated with reduced-intensity conditioning (RIC, n=87) or conventional myeloablative (CONV, n=44) MUD-SCT between 2000 and 2005 were included. Median time from diagnosis to MUD-SCT was 47 months and the median number of previous therapeutic regimens was 4 (previous autograft : 47%). RIC recipients were significantly older, with a longer interval from diagnosis to MUD-SCT and had failed a previous autograft more frequently than CONV recipients. Non-relapse mortality (NRM) was 24% and 30% at 100-d and 1-year, respectively. After a median follow-up of 36 months, 17% of the patients developed disease progression, the 3-year progression-freee survival (PFS) being 47%. Three-year overall survival (OS) for the whole series was 51%. On multivariate analysis, RIC regimens were associated with at lower NRM and a significantly longer PFS and OS. This retrospective study demonstrated that MUS-SCT results, even in heavily pre-treated populations, in a meaningful PFS and OS [less ▲]

Detailed reference viewed: 44 (16 ULg)
Full Text
Peer Reviewed
See detailAlone or in concert with glucocorticoids, genistein induces adipogenesis but inhibits leptin induction in human synovial fibroblasts
Relic, Biserka ULg; Zeddou, Mustapha ULg; Desoroux, Aline ULg et al

in Laboratory Investigation : Journal of Technical Methods & Pathology (2009), 89(7), 811-822

It was shown recently that synovial fibroblast transformation into adipocytes reduced the expression of interleukin-6 (IL-6) and IL-8. However, the synovial fibroblast adipogenesis was inhibited in ... [more ▼]

It was shown recently that synovial fibroblast transformation into adipocytes reduced the expression of interleukin-6 (IL-6) and IL-8. However, the synovial fibroblast adipogenesis was inhibited in inflammatory conditions induced by the tumor necrosis factor-alpha (TNF-alpha). Furthermore, adipogenesis is often accompanied by leptin production, a proinflammatory adipokine in rheumatic diseases. In this study, we tested the phytohormone genistein for adipogenic and anti-inflammatory properties on human synovial fibroblasts. Results showed that genistein was able to transform synovial fibroblasts into adipocytes that expressed perilipin-A and produced adiponectin, but not leptin. Furthermore, genistein enhanced glucocorticoid-mediated synovial fibroblast adipogenesis and, in parallel, downregulated glucocorticoid-induced leptin and leptin receptor. Endogenous and TNF-alpha-induced expressions of IL-6, IL-8, p38, p65 and C/EBP-beta were also downregulated by genistein, showing its anti-inflammatory properties. Peroxisome proliferator- activated receptor-gamma (PPAR-gamma) agonist, rosiglitazone, had a synergic effect on genistein-induced whereas the non-active tyrosine kinase inhibitor, daidzein, had a significantly inferior adipogenic activity than genistein. The Janus kinase-2 tyrosine kinase inhibitor, AG 490, mimicked the anti-leptin effect of genistein. These results showed that genistein-induced adipogenesis involves PPAR-gamma induction and tyrosine kinase inhibition. In conclusion, genistein, alone or coupled with glucocorticoids, have both adipogenic and anti-inflammatory effects on synovial fibroblasts. [less ▲]

Detailed reference viewed: 81 (18 ULg)
Full Text
Peer Reviewed
See detailCancers secondaires après allogreffe de cellules souches hématopoïétiques
Hafraoui, Kaoutar ULg; Beguin, Yves ULg; Baron, Frédéric ULg

in Revue Médicale de Liège (2009), 64(10), 496-499

This article reviews the incidence, risk factors and prevention of secondary malignancies after allogeneic hematopoietic cell transplantation.

Detailed reference viewed: 106 (10 ULg)
Full Text
Peer Reviewed
See detailImpact of growth hormone (GH) deficiency and GH replacement upon thymus function in adult patients.
Morrhaye, Gabriel ULg; Kermani, Hamid; Legros, Jean-Jacques ULg et al

in PLoS ONE (2009), 4(5), 5668

BACKGROUND: Despite age-related adipose involution, T cell generation in the thymus (thymopoiesis) is maintained beyond puberty in adults. In rodents, growth hormone (GH), insulin-like growth factor-1 ... [more ▼]

BACKGROUND: Despite age-related adipose involution, T cell generation in the thymus (thymopoiesis) is maintained beyond puberty in adults. In rodents, growth hormone (GH), insulin-like growth factor-1 (IGF-1), and GH secretagogues reverse age-related changes in thymus cytoarchitecture and increase thymopoiesis. GH administration also enhances thymic mass and function in HIV-infected patients. Until now, thymic function has not been investigated in adult GH deficiency (AGHD). The objective of this clinical study was to evaluate thymic function in AGHD, as well as the repercussion upon thymopoiesis of GH treatment for restoration of GH/IGF-1 physiological levels. METHODOLOGY/PRINCIPAL FINDINGS: Twenty-two patients with documented AGHD were enrolled in this study. The following parameters were measured: plasma IGF-1 concentrations, signal-joint T-cell receptor excision circle (sjTREC) frequency, and sj/beta TREC ratio. Analyses were performed at three time points: firstly on GH treatment at maintenance dose, secondly one month after GH withdrawal, and thirdly one month after GH resumption. After 1-month interruption of GH treatment, both plasma IGF-1 concentrations and sjTREC frequency were decreased (p<0.001). Decreases in IGF-1 and sjTREC levels were correlated (r = 0.61, p<0.01). There was also a decrease in intrathymic T cell proliferation as indicated by the reduced sj/beta TREC ratio (p<0.01). One month after reintroduction of GH treatment, IGF-1 concentration and sjTREC frequency regained a level equivalent to the one before GH withdrawal. The sj/beta TREC ratio also increased with GH resumption, but did not return to the level measured before GH withdrawal. CONCLUSIONS: In patients with AGHD under GH treatment, GH withdrawal decreases thymic T cell output, as well as intrathymic T cell proliferation. These parameters of thymus function are completely or partially restored one month after GH resumption. These data indicate that the functional integrity of the somatotrope GH/IGF-1 axis is important for the maintenance of a normal thymus function in human adults. TRIAL REGISTRATION: ClinicalTrials.gov NTC00601419. [less ▲]

Detailed reference viewed: 153 (29 ULg)
Full Text
Peer Reviewed
See detailInhibition of the Jagged-1/Notch pathway increases the hematopoiesis-supportive activity of mesenchymal stem cells
Briquet, Alexandra ULg; Dolhet, Marie; Beguin, Yves ULg et al

in Experimental Hematology (2009), 37(9), 77

Detailed reference viewed: 25 (10 ULg)
Full Text
Peer Reviewed
See detailToxoplasmore cérébrale compliquant une mini-allogreffe de cellules souches hématopoïétiques du sang périphérique
Dugauquier, C.; Bataille, Y.; Willems, Evelyne ULg et al

in Revue Médicale de Liège (2009), 64(7-8), 366-369

We report the occurrence of a cerebral toxoplasmosis 52 days after a non-myeloablative allogeneic stem cell transplantation as treatment for acute myeloid leukemia.

Detailed reference viewed: 85 (7 ULg)
Full Text
Peer Reviewed
See detailPulmonary veno-occlusive disease in myeloproliferative disorder.
Willems, Evelyne ULg; Canivet, Jean-Luc ULg; Ghaye, Benoît ULg et al

in European Respiratory Journal (2009), 33(1), 213-216

The present study reports a case of biopsy-proven pulmonary veno-occlusive disease as a cause of severe pulmonary hypertension in a patient suffering from a chronic myeloproliferative disorder. The ... [more ▼]

The present study reports a case of biopsy-proven pulmonary veno-occlusive disease as a cause of severe pulmonary hypertension in a patient suffering from a chronic myeloproliferative disorder. The pulmonary disease evolved favourably under treatment with defibrotide, a pro-fibrinolytic medication used in hepatic veno-occlusive disease. [less ▲]

Detailed reference viewed: 65 (22 ULg)
Full Text
Peer Reviewed
See detailLes anticorps monoclonaux en hématologie en 2009
Bonnet, Christophe ULg; Beguin, Yves ULg; De Prijck, Bernard ULg et al

in Revue Médicale de Liège (2009), 64

Directed against the CD20 antigen on B lymphocytes, rituximab (MabThera) is now incorporated in the first line therapy of symptomatic follicular as well as diffuse large B cell non-Hodgkin's lymphoma and ... [more ▼]

Directed against the CD20 antigen on B lymphocytes, rituximab (MabThera) is now incorporated in the first line therapy of symptomatic follicular as well as diffuse large B cell non-Hodgkin's lymphoma and offers superior response and survival rates. 90Y ibritumomab tiuxetan (Zevalin) combines the specificity of rituximab for the CD20 antigen and the therapeutic effect of β irradiation. Given in monotherapy, it constitutes an interesting alternative therapy for follicular lymphomas in second relapse. Alemtuzumab (MabCampath) recognizes the CD52 antigen and offers encouraging results in chronic lymphocytic leukemia resistant to classical chemotherapy. [less ▲]

Detailed reference viewed: 184 (14 ULg)
Full Text
Peer Reviewed
See detailTraitements actuels du lymphome folliculaire
Bonnet, Christophe ULg; Beguin, Yves ULg; De Prijck, Bernard ULg et al

in Revue Médicale Suisse (2009), 5

After diffuse large B-cell lymphoma, follicular lymphoma is the most frequent non-Hodgkin's lymphoma. It remains incurable, except for localized diseases. Advanced disease has to be treated only in the ... [more ▼]

After diffuse large B-cell lymphoma, follicular lymphoma is the most frequent non-Hodgkin's lymphoma. It remains incurable, except for localized diseases. Advanced disease has to be treated only in the presence of clinical and/or biology aggressiveness. These patients should be treated by rituximab (Mab-Thera) associated to polychemotherapy comprising cyclophosphamide, vincristine and prednisone. After this therapy, the benefit of rituximab in maintenance has to be confirmed. Autologous stem cell transplantation is also an interesting option. The other therapeutic options comprise radio-immunotherapy with 90Y ibritumomab tiuxetan (Zevalin) and bortezomib (Velcade). [less ▲]

Detailed reference viewed: 440 (5 ULg)
Full Text
Peer Reviewed
See detailEx vivo expansion of hematopoietic progenitor cells is associated with downregulation of alpha4 integrin- and CXCR4-mediated engraftment in NOD/SCID beta2-microglobulin-null mice
Foguenne, Jacques ULg; Di Stefano; Giet, Olivier ULg et al

in Haematologica (2009), 94

Several studies indicate that ex vivo cytokine-supported expansion induces defective hematopoietic stem cell engraftment. We investigated the role of alpha4 integrin, alpha5 integrin and CXCR4 in ... [more ▼]

Several studies indicate that ex vivo cytokine-supported expansion induces defective hematopoietic stem cell engraftment. We investigated the role of alpha4 integrin, alpha5 integrin and CXCR4 in engraftment of unmanipulated and cytokine-treated human cord blood CD34+ cells. [less ▲]

Detailed reference viewed: 39 (18 ULg)
Full Text
Peer Reviewed
See detailKIR-ligand incompatibility in the Graft-versus-host direction improves outcome after umbilical cord blood transplantation for acute leukemia
Willemze, R.; Rodrigues, C. A.; Labopin, M. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2009), 23

Detailed reference viewed: 29 (5 ULg)
Full Text
Peer Reviewed
See detailUtilisation thérapeutique de l'érythropoïétine
Beguin, Yves ULg

in Revue du Praticien (La) (2009), 59

Detailed reference viewed: 40 (9 ULg)
Full Text
Peer Reviewed
See detailWhat is the Role for Regulatory T-Cells after Nonmyeloablative conditioning
Humblet-Baron, S.; CASTERMANS, Emilie ULg; Vanbellighen, J.-F. et al

in Biology of Blood & Marrow Transplantation (2008, February), 14(2), 136-137

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailCord blood banking
Brand, A.; Rebulla, P.; Engelfriet, C. P. et al

in Vox Sanguinis (2008), 95

Detailed reference viewed: 82 (3 ULg)
Full Text
Peer Reviewed
See detailEvidence for neo-generation of T cells by the thymus after non-myeloablative conditioning.
Castermans, Emilie ULg; Baron, Frédéric ULg; Willems, Evelyne ULg et al

in Haematologica (2008), 93(2), 240-7

BACKGROUND: Background and objective. We investigated immune recovery in 50 patients given either unmanipulated or CD8-depleted allogeneic peripheral blood stem cells after non-myeloablative conditioning ... [more ▼]

BACKGROUND: Background and objective. We investigated immune recovery in 50 patients given either unmanipulated or CD8-depleted allogeneic peripheral blood stem cells after non-myeloablative conditioning. DESIGN AND METHODS: Fifty patients were randomized to receive either CD8-depleted (n=22) or non-manipulated (n=28) peripheral blood stem cells. The median patients age was 57 (range 36-69) years. The conditioning regimen consisted of 2 Gy total body irradiation with or without added fludarabine. Twenty patients received grafts from related donors, 14 from 10/10 HLA-allele matched unrelated donors, and 16 from HLA-mismatched unrelated donors. Graft-versus-host disease pro-phylaxis consisted of mycophenolate mofetil and cyclosporine. Immune recovery during the first year after hematopoietic cell transplantation was assessed by flow cytometry phenotyping, analyses of the diversity of the TCRBV repertoire, and quantification of signal-joint T-cell receptor excision circles (sjTREC). RESULTS: CD8-depletion of the graft reduced the recovery of CD8(+) T-cell counts in the first 6 months following transplantation (p<0.0001) but had no significant impact on the restoration of other T-cell subsets. Both sjTREC concentration and CD3(+) T-cell counts increased significantly between day 100 and 365 (p=0.010 and p=0.0488, respectively) demonstrating neo-production of T cells by the thymus. Factors associated with high sjTREC concentration 1 year after transplantation included an HLA-matched unrelated donor (p=0.029), a high content of T cells in the graft (p=0.002), and the absence of chronic graft-versus-host disease (p<0.0001). CONCLUSIONS: Our data suggest that while immune recovery is mainly driven by peripheral expansion of the graft-contained mature T cells during the first months after non-myeloablative transplantation, T-cell neo-generation by the thymus plays an important role in long term immune reconstitution in transplanted patients. [less ▲]

Detailed reference viewed: 159 (85 ULg)
Full Text
See detailPrediction of response to recombinant human erythropoietin in the anemia of cancer
Beguin, Yves ULg; Vanstraelen, Gaetan

in Nowrousian, M. R. (Ed.) Recombinant human erythropoietin (rhEPO) in clinical oncology (2nd Ed.) (2008)

Detailed reference viewed: 12 (1 ULg)
Full Text
See detailrhEPO in hematopoietic stem cell transplantation
Vanstraelen, Gaetan; Beguin, Yves ULg

in Nowrousian, M. R. (Ed.) Recombinant human erythropoietin (rhEPO) in clinical oncology (2nd Ed.) (2008)

Detailed reference viewed: 12 (3 ULg)
Full Text
Peer Reviewed
See detailComment je traite...La leucémie myéloblastique aiguë (LMA) du sujet age en bon état général.
Lejeune, Marie ULg; Beguin, Yves ULg; De Prijck, Bernard ULg et al

in Revue Médicale de Liège (2008), 63(2), 59-63

This article describes the treatment of acute myeloid leukemia in older patients with good performance status, and then discusses briefly some future therapeutic perspectives.

Detailed reference viewed: 169 (11 ULg)
Full Text
Peer Reviewed
See detailCord blood transplantation in a child with Pearson's disease.
Hoyoux, Claire; Dresse, Marie-Françoise ULg; Robinet, Sébastien ULg et al

in Pediatric Blood & Cancer (2008), 51(4), 566

Detailed reference viewed: 40 (4 ULg)